NASDAQ:VRTX

Vertex Pharmaceuticals Stock News

etoro logo Buy VRTX
*Your capital is at risk
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Aberdeen Group plc lowered its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 16.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exc
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.75, moving 1.9% from the previous trading session.
Vertex Pharmaceuticals (VRTX) remains a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. VRTX's new label expansions now cover 95% of U.S.
F&V Capital Management LLC bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) during the undefined quarter, according to the company in its most recent 13F filing with the Securi
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/
Boston Common Asset Management LLC trimmed its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 51.2% during the undefined quarter, according to the company in its most rece
Beacon Investment Advisory Services Inc. decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 2.7% during the fourth quarter, according to its most recent filing w
Multiple headwinds could bring the bull market to a halt. Stocks positioned to rise even during a market downturn include Berkshire Hathaway, Enbridge, and Vertex Pharmaceuticals.
Congress Asset Management Co. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 99.4% in the fourth quarter, according to its most recent disclosure with the SEC. The fund
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the twenty-nine brokerages that are covering the company, Marke
Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $454.97, signifying a +1.42% move from its prior day's close.
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Gradient Investments LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 6.4% in the fourth quarter, according to the company in its most recent Form 13F filing wi
Nordea Investment Management AB boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 23.8% in the fourth quarter, according to its most recent filing with the SEC. T
Grove Bank and Trust increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 374.7% during the undefined quarter, according to the company in its most recent 13F fili
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE